RNA Therapeutics Market to Hit $2.32B by 2032, Fueled by mRNA Expansion
Event summary
- RNA-based therapeutics and vaccines market projected to reach $2.32B by 2032, growing at a CAGR of 5.50% from 2025–2032.
- Market valued at $1.285B in 2024, driven by clinical success and rising investments in advanced biologics.
- mRNA vaccines, siRNA, and antisense oligonucleotides are key technologies enabling precision targeting of diseases.
- North America leads the market, while Asia-Pacific is the fastest-growing region due to biotech investments and manufacturing scale.
The big picture
The RNA therapeutics market is expanding beyond infectious diseases into cardiometabolic, autoimmune, and central nervous system therapies. The success of mRNA vaccines during the COVID-19 pandemic has accelerated research activity and industry confidence, positioning RNA-based therapeutics as a long-term growth engine for the biopharmaceutical sector. The market is supported by rapid platform diversification, manufacturing scale-up, and deeper clinical validation across multiple disease areas.
What we're watching
- Technology Diversification
- The pace at which self-amplifying RNA (saRNA) and circular RNA technologies advance will determine long-term commercial viability.
- Regulatory Approvals
- The speed of regulatory reviews for mRNA-based therapies beyond infectious diseases, particularly in oncology and rare genetic disorders.
- Manufacturing Scale-Up
- Whether regional manufacturing hubs can meet the demand for RNA-based therapeutics and vaccines globally.
Related topics